| 19th Mar 2020 7:00 am |
RNS |
Lynparza granted orphan drug designation in Japan |
| 17th Mar 2020 7:00 am |
RNS |
Imfinzi confirmed overall survival in CASPIAN |
| 13th Mar 2020 4:35 pm |
RNS |
Price Monitoring Extension |
| 12th Mar 2020 11:00 am |
RNS |
Notice of AGM |
| 12th Mar 2020 7:00 am |
RNS |
Update on Phase III GY004 trial for cediranib |
| 10th Mar 2020 7:00 am |
RNS |
Director/PDMR Shareholding |
| 6th Mar 2020 7:00 am |
RNS |
Update on Phase III DANUBE trial in bladder cancer |
| 4th Mar 2020 7:00 am |
RNS |
Filing of Form 20-F with SEC |
| 3rd Mar 2020 11:00 am |
RNS |
Annual Financial Report |
| 2nd Mar 2020 3:00 pm |
RNS |
Total Voting Rights |
| 2nd Mar 2020 7:00 am |
RNS |
Divestment of hypertension medicines completed |
| 27th Feb 2020 7:00 am |
RNS |
Director/PDMR Shareholding |
| 25th Feb 2020 7:00 am |
RNS |
AstraZeneca divests global rights to Movantik |
| 19th Feb 2020 7:00 am |
RNS |
Director/PDMR Shareholding |
| 14th Feb 2020 7:00 am |
RNS |
AZN: Full-year and Q4 2019 results |
| 3rd Feb 2020 3:00 pm |
RNS |
Total Voting Rights |
| 27th Jan 2020 7:00 am |
RNS |
Enhertu Phase II trial met primary endpoint |
| 27th Jan 2020 7:00 am |
RNS |
Brilinta met primary endpoint in stroke trial |
| 27th Jan 2020 7:00 am |
RNS |
AstraZeneca divests hypertension medicines |
| 27th Jan 2020 7:00 am |
RNS |
AstraZeneca to recover brazikumab (MEDI2070) |
| 20th Jan 2020 7:00 am |
RNS |
FDA grants Lynparza Priority Review for PROfound |
| 20th Jan 2020 7:00 am |
RNS |
Imfinzi, tremelimumab granted ODD in liver cancer |
| 13th Jan 2020 7:01 am |
RNS |
Lynparza granted FDA Priority Review for PAOLA-1 |
| 13th Jan 2020 7:00 am |
RNS |
Update on Epanova Phase III STRENGTH trial |
| 6th Jan 2020 7:01 am |
RNS |
Farxiga granted FDA heart failure Priority Review |
| 6th Jan 2020 7:00 am |
RNS |
Lokelma approved in China for hyperkalaemia |
| 2nd Jan 2020 3:00 pm |
RNS |
Total Voting Rights |
| 30th Dec 2019 7:00 am |
RNS |
US FDA approved Lynparza for pancreatic cancer |
| 23rd Dec 2019 7:00 am |
RNS |
Triple-combination approved in China for COPD |
| 23rd Dec 2019 7:00 am |
RNS |
Enhertu (trastuzumab deruxtecan) approved in US |
| 20th Dec 2019 7:00 am |
RNS |
AstraZeneca divests rights to Arimidex and Casodex |
| 17th Dec 2019 6:06 pm |
RNS |
FDA panel backs Lynparza use for pancreatic cancer |
| 16th Dec 2019 7:00 am |
RNS |
Seroquel rights agreement complete: Europe, Russia |
| 12th Dec 2019 7:00 am |
RNS |
Imfinzi approved in China for Stage III NSCLC |
| 11th Dec 2019 1:00 pm |
RNS |
Trastuzumab deruxtecan achieves ORR of 60.9% |
| 5th Dec 2019 7:00 am |
RNS |
Lynparza approved in China for 1L BRCAm ovarian |
| 3rd Dec 2019 7:00 am |
RNS |
AstraZeneca divests Seroquel rights: US and Canada |
| 2nd Dec 2019 3:00 pm |
RNS |
Block listing Interim Review |
| 2nd Dec 2019 3:00 pm |
RNS |
Total Voting Rights |
| 29th Nov 2019 7:00 am |
RNS |
Imfinzi granted FDA Priority Review for SCLC |
